Entacapone,Levodopa and Carbidopa Tablets(II)
Properties:This product is a brown-red or gray-red film-coated tablet, yellow or orange-yellow after removing the coating, and white spots.
Indications:It is used for the treatment of adult patients with Parkinson's disease who can be controlled by zosendopa/dopa decarboxylase (DDC) inhibitor therapy.
Dosage:The medicine can be taken on an empty stomach or after meals. One tablet contains one therapeutic dose. The tablets should be swallowed whole. Patients should take only one tablet at a time. Patients taking less than 70-100 mg of carbidopa per day are more likely to experience nausea and vomiting. Clinical experience with carbidopa doses exceeding 300 mg per day is limited, whereas the recommended maximum daily dose of entacapone is 1600 mg. Therefore, the maximum daily dose of this product is 8 tablets per day. Usually this product is used in patients who have been treated with levodopa/dopa deaminase inhibitors and entacapone in the corresponding dose of standard-release dosage form. Switched from levodopa/dopa deaminase inhibitors (carbidopa or benserazide) and entacapone tablets to this product. a, are receiving the same dose of entacapone and the standard release dosage form of levodopa
Adverse reactions:The most commonly reported adverse reactions of carbidopa-levodopa include movement disorders such as chorea, dystonia, other involuntary movements, and nausea. The most common adverse reactions (5%) observed in a double-blind, placebo-controlled clinical trial (n=1003) of entacapone were: dyskinesia/hyperkinesia, nausea, urine discoloration, diarrhea, box abdominal pain.
[Contraindications] 1. Allergy to the active ingredient of this product (carbidopa, levodopa or entacapone) or any of the excipients 2. Monoamine oxidase (MAO) and COMT are the two main enzyme systems in catecholamine metabolism. As with levodopa/carbidopa, non-selective monoamine oxidase inhibitors are contraindicated for use with this product. 3. Narrow-angle glaucoma. 4. Because levodopa may activate malignant melanoma, patients with suspicious and undiagnosed skin lesions or a history of melanoma are prohibited from taking this product.
Precautions:1. Similar to taking levodopa, when using this product for long-term treatment, it is recommended to evaluate the liver, hematopoiesis, cardiovascular box and kidney function for four years. 2. Patients with chronic open-angle glaucoma should pay attention to the treatment with this product, and before starting to use this product, the patient's intraocular pressure should be well controlled, and the changes in intraocular pressure should be carefully monitored. Please read the instructions carefully and use as directed by your healthcare professional.
Shijiazhuang No.4 Pharmaceutical Co., Ltd. was established in 1948, now it is a large-sized foreign invested enterprise and comprehensive medicine manufacturer in China, the capital is USD58 million, and with more than 3000 employees. The company can manufacture 7 series medicines of more than 100 kinds and specifications including infusions, capsules, granules, tablets, oral liquids and etc with GMP approval by SFDA of China. For the key product of large volume I.V solution, the yearly output has reached more than 1200 million bottles including 40 million bottles packing with the soft plastic bottles in the dosage of 500 ml/ 250 ml /100ml. Some index such as quality, variety, and yearly output are all in the leading position of this field in China.
The products have been sold to some countries and regions in South America, Africa, and Asia.
Audited Supplier 
){kind=link}